TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers
The primary to assess the safety and tolerability of TA-CIN and anti-PD-1 therapy in patients with recurrent HPV16-associated cancers and to assess the feasibility of IT injection of TA-CIN in patients with recurrent HPV16-associated cancers undergoing treatment with anti-PD-1 therapy.
Recurrent Human Papillomavirus Type 16 Associated Cancer
DRUG: HPV 16 TA-CIN
Number of patients who successfully receive at least one intratumoral vaccination, 10 weeks
The primary to assess the safety and tolerability of TA-CIN and anti-PD-1 therapy in patients with recurrent HPV16-associated cancers and to assess the feasibility of IT injection of TA-CIN in patients with recurrent HPV16-associated cancers undergoing treatment with anti-PD-1 therapy.